The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $8.31 in the last session, up 1.96% from day before closing price of $8.15. In other words, the price has increased by $1.96 from its previous closing price. On the day, 1.06 million shares were traded. DNA stock price reached its highest trading level at $8.31 during the session, while it also had its lowest trading level at $8.08.
Ratios:
We take a closer look at DNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.76.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 15 ’25 when Coen Steven P. sold 736 shares for $8.89 per share. The transaction valued at 6,540 led to the insider holds 7,488 shares of the business.
Coen Steven P. bought 736 shares of DNA for $6,540 on Dec 15 ’25. On Dec 10 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 2,200 shares for $9.54 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 503504768 and an Enterprise Value of 433317216. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.79 while its Price-to-Book (P/B) ratio in mrq is 0.80. Its current Enterprise Value per Revenue stands at 2.399 whereas that against EBITDA is -1.594.
Stock Price History:
The Beta on a monthly basis for DNA is 1.56, which has changed by -0.27989602 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $17.58, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -13.93%, while the 200-Day Moving Average is calculated to be -17.08%.
Shares Statistics:
According to the various share statistics, DNA traded on average about 1.28M shares per day over the past 3-months and 1001590 shares per day over the past 10 days. A total of 45.32M shares are outstanding, with a floating share count of 42.40M. Insiders hold about 26.37% of the company’s shares, while institutions hold 54.97% stake in the company. Shares short for DNA as of 1765756800 were 6493151 with a Short Ratio of 5.05, compared to 1763078400 on 7043448. Therefore, it implies a Short% of Shares Outstanding of 6493151 and a Short% of Float of 13.719999999999999.
Earnings Estimates
. The current market rating for Ginkgo Bioworks Holdings Inc (DNA) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.13, with high estimates of -$1.13 and low estimates of -$1.13.
Analysts are recommending an EPS of between -$5.35 and -$5.94 for the fiscal current year, implying an average EPS of -$5.64. EPS for the following year is -$4.15, with 3.0 analysts recommending between -$3.51 and -$4.62.
Revenue Estimates
According to 4 analysts,. The current quarter’s revenue is expected to be $37.69M. It ranges from a high estimate of $39.5M to a low estimate of $35.57M. As of. The current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $43.85MFor the next quarter, 4 analysts are estimating revenue of $44.27M. There is a high estimate of $47.3M for the next quarter, whereas the lowest estimate is $38.5M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $176.3M, while the lowest revenue estimate was $172.33M, resulting in an average revenue estimate of $174.48M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $191.21M in the next fiscal year. The high estimate is $205M and the low estimate is $164.8M.
